Objectives: In multisite human immunodeficiency virus (HIV) observational cohorts, clustering of observations often occurs within sites. Ignoring clustering may lead to "Simpson's paradox" (SP) where the trend observed in the aggregated data is reversed when the groups are separated. This study aimed to investigate the SP in an Asian HIV cohort and the effects of site-level adjustment through various Cox regression models.
Study Design And Setting: Survival time from combination antiretroviral therapy (cART) initiation was analyzed using four Cox models: (1) no site adjustment; (2) site as a fixed effect; (3) stratification through site; and (4) shared frailty on site.
Results: A total of 6,454 patients were included from 23 sites in Asia. SP was evident in the year of cART initiation variable. Model (1) shows the hazard ratio (HR) for years 2010-2014 was higher than the HR for 2006-2009, compared to 2003-2005 (HR = 0.68 vs. 0.61). Models (2)-(4) consistently implied greater improvement in survival for those who initiated in 2010-2014 than 2006-2009 contrasting findings from model (1). The effects of other significant covariates on survival were similar across four models.
Conclusions: Ignoring site can lead to SP causing reversal of treatment effects. Greater emphasis should be made to include site in survival models when possible.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4974156 | PMC |
| http://dx.doi.org/10.1016/j.jclinepi.2016.01.030 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical characterisation and outcomes of human clade IIb mpox virus disease - a European multicentre observational cohort study (MOSAIC).
Clin Infect Dis
January 2025
ISARIC - Pandemic Sciences Institute, University of Oxford, United Kingdom.
Background: The global mpox outbreak which started in May 2022 was caused by a novel clade IIb variant of the mpox virus (MPXV). It differed from the traditional Western and Central Africa disease in transmission patterns and clinical presentation.
Methods: To address the need for detailed clinical and virologic data, we conducted an observational cohort study (MOSAIC) during May 2022-July 2023 in individuals with confirmed MPXV infection enrolled in six European Countries.
Adherence and forgiveness of two modern ART regimens: lamivudine/dolutegravir and emtricitabine/tenofovir alafenamide/rilpivirine.
J Acquir Immune Defic Syndr
January 2025
Infectious Disease Clinic, IRCCS Policlinico San Martino Hospital, Genoa.
Introduction: Few data are available about the forgiveness of two-drug (2DR) or low-barrier three-drug antiretroviral regimens. The aim of this study is to evaluate the real-life forgiveness of lamivudine/dolutegravir (3TC/DTG) and emtricitabine/tenofovir alafenamide/rilpivirine (FTC/TAF/RPV).
Methods: A two center retrospective observational study enrolled all people with HIV (PWH) treated with 3TC/DTG or FTC/TAF/RPV.
Examining Bi-directional links between distinct affect states and tobacco lapse during a cessation attempt.
Drug Alcohol Depend
December 2024
Center for Health Outcomes and Population Equity (HOPE), Huntsman Cancer Institute and the University of Utah, United States; Department of Population Health Sciences, University of Utah, United States.
Background: Theoretical models of addiction highlight the bi-directional links of certain distinct affect states and tobacco lapse, but to date, few studies have examined bi-directional associations, instead examining associations with global affect measures (e.g., negative affect versus feelings of guilt).
View Article and Find Full Text PDFReal-life study on the effectiveness and safety of sofosbuvir/velpatasvir-based antiviral agents for hepatitis C eradication in Chinese patients.
J Virus Erad
December 2024
Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, 610041, China.
Background: Hepatitis C virus (HCV) eradication with sofosbuvir/velpatasvir (SOF/VEL) represents a significant advancement, offering hope for eliminating the virus in diverse patient populations. But real-world data on its effectiveness and safety remains scarce for patients with chronic hepatitis C (CHC) in China, especially those with HCV GT3b, cirrhosis, hepato-cellular carcinoma (HCC), or HCV/hepatitis B (HBV), HCV/HIV, or HCV/HBV/HIV coinfection.
Methods: In this real-world prospective observational study, we recruited patients from the West China Hospital and Public Health Clinical Center of Chengdu in China.
The prevalence of Chlamydia trachomatis infection by Nucleic Acid Amplification test in women of reproductive age group under treatment for infertility.
Med J Armed Forces India
December 2024
Associate Professor (Obst & Gynae), Military Hospital Roorkee, India.
Background: In India, the prevalence of Chlamydia Trachomatis (CT) studies in different groups are focused on high-risk populations - HIV-positive women and female sex workers - and have shown a variable prevalence rate ranging from 1.1 to 45%. One concern about comparing these studies is that the enzyme-linked immunosorbent assay (ELISA) test is estimated to be only 65-70% sensitive.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!